Biocon to acquire Biocon Biologics debentures, announces final dividend TDS

Biocon (BSE: 532523) announced its Board of Directors has approved the acquisition of Optionally Convertible Debentures (OCDs) of its unlisted subsidiary, Biocon Biologics Limited, from Goldman Sachs India Alternative Investment Trust AIF Scheme - 2 and Goldman Sachs India AIF Scheme-1. The acquisition involves 1,125 unlisted, unsecured, redeemable OCDs with a face value of INR 10,000,000 each, for a total consideration of approximately USD 198.50 million.